Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment

Inclusion criteria : * Male or female subjects, between 18 and 75 years of age, inclusive. * Body weight between 50.0 and 115.0 kg, inclusive if male, and between 40.0 and 100.0 kg, inclusive if female, body mass index between 18.0 and 34.9 kg/m2, inclusive. * Stable chronic liver disease with Child-Pugh classification score between 5 and 9 assessed by medical history, physical examination, laboratory values * 12-lead ECG without clinically significant abnormality * Laboratory parameters within the acceptable range for subjects with hepatic impairment * Using a double contraception method Exclusion criteria: * Uncontrolled clinically relevant cardiovascular, pulmonary, gastrointestinal, metabolic, hematological, neurological, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness. * Hepatocarcinoma. * Acute hepatitis * Any significant change in chronic treatment medication within 14 days before inclusion * Concomitant treatment with or use of drugs or herbal agents known to be at least moderate inhibitors or inducers CYP3A4 sensitive or narrow therapeutic index substrate of CYP3A4 * Concomitant treatment gastric pH modifying agent * Positive result on any of the following tests: anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV1 and anti HIV2 Ab). * Positive result on urine drug screen * Positive alcohol test. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.